- Home
- JBHT vs INCY Comparison
JBHT vs INCY Comparison
Compare JBHT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBHT
- INCY
- Stock Information
- Founded
- JBHT 1961
- INCY 1991
- Country
- JBHT United States
- INCY United States
- Employees
- JBHT N/A
- INCY N/A
- Industry
- JBHT Trucking Freight/Courier Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- JBHT Industrials
- INCY Health Care
- Exchange
- JBHT Nasdaq
- INCY Nasdaq
- Market Cap
- JBHT 14.4B
- INCY 13.0B
- IPO Year
- JBHT N/A
- INCY 1993
- Fundamental
- Price
- JBHT $143.45
- INCY $86.92
- Analyst Decision
- JBHT Buy
- INCY Buy
- Analyst Count
- JBHT 19
- INCY 20
- Target Price
- JBHT $168.58
- INCY $79.06
- AVG Volume (30 Days)
- JBHT 1.0M
- INCY 1.9M
- Earning Date
- JBHT 07-15-2025
- INCY 07-29-2025
- Dividend Yield
- JBHT 1.23%
- INCY N/A
- EPS Growth
- JBHT N/A
- INCY 900.04
- EPS
- JBHT 5.51
- INCY 4.37
- Revenue
- JBHT $12,064,092,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- JBHT $1.38
- INCY $13.53
- Revenue Next Year
- JBHT $5.32
- INCY $10.38
- P/E Ratio
- JBHT $26.03
- INCY $19.90
- Revenue Growth
- JBHT N/A
- INCY 18.87
- 52 Week Low
- JBHT $122.79
- INCY $53.56
- 52 Week High
- JBHT $200.40
- INCY $87.06
- Technical
- Relative Strength Index (RSI)
- JBHT 47.68
- INCY 80.83
- Support Level
- JBHT $142.17
- INCY $76.45
- Resistance Level
- JBHT $146.07
- INCY $79.43
- Average True Range (ATR)
- JBHT 3.34
- INCY 2.57
- MACD
- JBHT 0.01
- INCY 1.01
- Stochastic Oscillator
- JBHT 53.34
- INCY 99.13
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.